[go: up one dir, main page]

MX2012004622A - Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof. - Google Patents

Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof.

Info

Publication number
MX2012004622A
MX2012004622A MX2012004622A MX2012004622A MX2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A MX 2012004622 A MX2012004622 A MX 2012004622A
Authority
MX
Mexico
Prior art keywords
adjuvant
vaccines
polypeptide
parts
lipidated
Prior art date
Application number
MX2012004622A
Other languages
Spanish (es)
Inventor
Mirta L Coria
Karina A Pasquevich
Andres E Ibanez
Guillermo H Giambartolomei
Juliana Cassataro
Maria Victoria Delpino
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Publication of MX2012004622A publication Critical patent/MX2012004622A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Adjuvant for vaccines that comprises a non-lipidated bacterial outer-membrane polypeptide (Omp), in which the bacteria may be those of the <i>Brucella</i> genus. The adjuvant may be a modified polypeptide or may, for example, be the Omp19S or Omp16S polypeptide, parts thereof or mixtures of the two. In a preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 1, or parts thereof. In a further preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 2, or parts thereof.
MX2012004622A 2009-10-19 2010-10-18 Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof. MX2012004622A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP090104015A AR073907A1 (en) 2009-10-19 2009-10-19 ADJUSTER FOR VACCINES, WHICH INCLUDES AN UNLIPPED POLIPEPTIDE FROM THE EXTERNAL MEMBRANE (OMP) OF BACTERIA, VACCINES THAT UNDERSTAND AND USES
PCT/ES2010/070667 WO2011048248A1 (en) 2009-10-19 2010-10-18 Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof

Publications (1)

Publication Number Publication Date
MX2012004622A true MX2012004622A (en) 2012-05-08

Family

ID=43566830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004622A MX2012004622A (en) 2009-10-19 2010-10-18 Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof.

Country Status (10)

Country Link
US (1) US9511137B2 (en)
EP (1) EP2491946B1 (en)
CN (1) CN102711815B (en)
AR (1) AR073907A1 (en)
BR (1) BR112012009239B1 (en)
CA (1) CA2778359C (en)
DK (1) DK2491946T3 (en)
ES (1) ES2542973T3 (en)
MX (1) MX2012004622A (en)
WO (1) WO2011048248A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106117365B (en) * 2016-06-23 2018-07-27 湖南农业大学 Anti-streptococcus suis is sick and with the active fusion protein of autoimmunity and its preparation and application
CN106188307B (en) * 2016-07-06 2019-01-04 长沙爱科博生物科技有限公司 A kind of fusion protein, preparation method and a boar oral vaccine or drug
CN107375922B (en) * 2017-07-20 2020-06-09 南京农业大学 A water-soluble compound immune adjuvant and porcine circovirus disease vaccine
US11459575B2 (en) * 2018-02-09 2022-10-04 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet Immunomodulating and immunostimulating ecotin polypeptides from Salmonella for drug-delivery
CN109486846B (en) * 2018-12-29 2021-08-20 山东农业大学 A Brucella three-gene recombinant plasmid, construction method and its expression and application in Escherichia coli
CN114073762B (en) * 2020-08-12 2023-07-21 中国人民解放军军事科学院军事医学研究院 A two-component vaccine against brucellosis containing Omp19 and VirB8 proteins
CN115267204A (en) * 2022-08-02 2022-11-01 中国农业科学院北京畜牧兽医研究所 Method and kit for evaluating immunity of flocks to brucellosis vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816844A1 (en) * 2000-11-17 2002-05-24 Pf Medicament Composition containing enterobacterial outer membrane peptides, useful e.g. as vaccine carrier or adjuvant, derived from the protein's periplasmic domain
ES2190350B1 (en) * 2001-07-31 2005-01-01 Jose Instituto Cientifico Y Tecnologico De Navarra, S.A(67%) COMPOSITION OF VACCINE AGAINST BRUCELOSIS THAT INCLUDES POLY MICROPARTICLES OF POLY (E-CAPROLACTONE) AS AN ASSISTANT.

Also Published As

Publication number Publication date
CN102711815B (en) 2015-05-20
CA2778359A1 (en) 2011-04-28
US9511137B2 (en) 2016-12-06
CA2778359C (en) 2019-07-16
EP2491946A1 (en) 2012-08-29
AR073907A1 (en) 2010-12-09
WO2011048248A1 (en) 2011-04-28
BR112012009239B1 (en) 2021-10-13
CN102711815A (en) 2012-10-03
ES2542973T3 (en) 2015-08-13
US20120258145A1 (en) 2012-10-11
EP2491946B1 (en) 2015-04-22
EP2491946A4 (en) 2013-06-19
DK2491946T3 (en) 2015-07-27
BR112012009239A2 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
MX2012004622A (en) Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof.
MX2009010800A (en) Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2011009515A (en) Motion inducing reverse shoulder assembly.
MX2009008928A (en) Compositions comprising polysaccharide conjugates and their use as vaccines.
WO2008115319A3 (en) Conjugates of synthetic tlr agonists and uses therefor
BRPI0417823A (en) methods for using probiotic bifidobacteria for pets
ZA200609500B (en) Adjuvanted Shiga toxin B-subunit based vaccines
MX2008001652A (en) Polyammonium/polysiloxane copolymers.
MX2010008423A (en) Treatment of microbial infections.
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
MX2009005460A (en) (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs.
MX2010002867A (en) Live attenuated mycoplasma strains.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
MX2010000864A (en) Inactivated staphylococcal whole-cell vaccine.
CL2008003659A1 (en) Compounds derived from 6- (4-benzylpiperazin-1-yl) pyrimidin-4-one, modulators of the enzyme stearoyl-coa-desaturase 1; preparation procedure; pharmaceutical composition; and use in the treatment and prophylaxis of obesity.
NZ594011A (en) Deoxyactagardine derivatives
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
EP1572918A4 (en) Synthetic glyco-lipo-peptides as vaccines
ATE523204T1 (en) CD44V6 PEPTIDES AS BACTERIAL INFECTION INHIBITORS
MX2009003300A (en) Recombinant rhinovirus vectors.
MX2011004176A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same.
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2009105192A3 (en) Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
WO2007086898A3 (en) Methods and compositions related to anthrax spore glycoproteins